{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T02:28:21Z","timestamp":1792549701010,"version":"4.5.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T00:00:00Z","timestamp":1746748800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005760","name":"University of Gothenburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005760","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patients with chronic kidney disease (CKD) have a high prevalence of cerebrovascular disease and cognitive impairment. The objective was to analyse whether plasma concentrations of neurofilament light chain (NfL), glial fibrillary acidic protein (GFAP) and phosphorylated Tau231 (p-Tau231) are elevated in patients with CKD and to identify independent predictors of these biomarkers, with an emphasis on the role of measured glomerular filtration rate (mGFR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      In this cross-sectional cohort study, we included 110 patients with CKD stages 3 and 4 (estimated GFR 15\u201359\u00a0ml\/min\/1.73\u00a0m\n                      <jats:sup>2<\/jats:sup>\n                      ) without manifest cerebrovascular disease or dementia, and 55 healthy controls. Biomarkers of neurological disorders were measured with ultrasensitive single molecule array methods.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Plasma concentrations (median [IQR]) of NfL (37.5 [22.1\u201347.5] vs. 13.4 [10.5\u201316.7] ng\/L,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), p-Tau231 (25.7 [19.1\u201338.7] vs. 13.9 [10.5\u201316.3] ng\/L,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and GFAP (190 [140\u2013281] vs. 153 [116\u2013211] ng\/L,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) were elevated in patients with CKD vs. controls. Measured GFR was negatively correlated with NfL (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u2009\u2212\u20090.706,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), p-Tau231 (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u2009\u2212\u20090.561,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001), and GFAP (\n                      <jats:italic>r<\/jats:italic>\n                      \u2009=\u2009\u2212\u20090.385,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). In multivariable linear regression models, mGFR was an independent predictor of log-transformed plasma concentrations of NfL (standardized beta coefficient [\u03b2]\u2009=\u2009\u2212\u20090.439,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001) and GFAP (\u03b2\u2009=\u2009\u2212\u20090.321,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Patients with CKD had elevated plasma concentrations of NfL, p-Tau231 and GFAP compared with controls, and these biomarkers were inversely correlated with mGFR. Measured GFR was a significant, independent predictor of plasma concentrations of NfL and GFAP in patients with CKD. The mechanisms underlying this association need further investigation. Plasma levels of NfL and GFAP should be interpreted cautiously in patients with marked reductions in GFR.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12882-025-04130-2","type":"journal-article","created":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T18:00:11Z","timestamp":1746813611000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Plasma concentrations of neurofilament light, p-Tau231 and glial fibrillary acidic protein are elevated in patients with chronic kidney disease and correlate with measured glomerular filtration rate"],"prefix":"10.1186","volume":"26","author":[{"given":"Torunn","family":"Axelsson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burak","family":"Arslan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"Ashton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Axelsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria K.","family":"Svensson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aso","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor","family":"Guron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,9]]},"reference":[{"issue":"1","key":"4130_CR1","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1093\/ndt\/gfr218","volume":"27","author":"P Muntner","year":"2012","unstructured":"Muntner P, Judd SE, McClellan W, Meschia JF, Warnock DG, Howard VJ.Incidence of stroke symptoms among adults with chronic kidney disease: results from the reasons for geographic and racial differences in stroke (REGARDS) study. Nephrol Dial Transplant. 2012;27(1):166\u201373.","journal-title":"Nephrol Dial Transplant"},{"key":"4130_CR2","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1053\/j.ajkd.2008.05.004","volume":"52","author":"M Kurella Tamura","year":"2008","unstructured":"Kurella Tamura M, Wadley V, Yaffe K, McClure LA, Howard G, Go R, et al. Kidney function and cognitive impairment in US adults: the reasons for geographic and racial differences in stroke (REGARDS) study. Am J Kidney Dis 2008;52:227\u201334.","journal-title":"Am J Kidney Dis"},{"key":"4130_CR3","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1159\/000346606","volume":"41","author":"BF Verhaaren","year":"2013","unstructured":"Verhaaren BF, Vernooij MW, Dehghan A, Vrooman HA, de Boer R, Hofman A, et al. The relation of uric acid to brain atrophy and cognition: the rotterdam scan study. Neuroepidemiology 2013;41:29\u201334.","journal-title":"Neuroepidemiology"},{"key":"4130_CR4","doi-asserted-by":"publisher","first-page":"481","DOI":"10.2459\/JCM.0000000000000005","volume":"15","author":"G Pulignano","year":"2014","unstructured":"Pulignano G, Del Sindaco D, Di Lenarda A, Tinti MD, Tarantini L, Cioffi G, et al. Chronic renal dysfunction and anaemia are associated with cognitive impairment in older patients with heart failure. J Cardiovasc Med (Hagerstown) 2014;15:481\u201390.","journal-title":"J Cardiovasc Med (Hagerstown)"},{"key":"4130_CR5","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.2215\/CJN.02240215","volume":"10","author":"R Xu","year":"2015","unstructured":"Xu R, Pi HC, Xiong ZY, Liao JL, Hao L, Liu GL, et al. Hyponatremia and cognitive impairment in patients treated with peritoneal dialysis. Clin J Am Soc Nephrol 2015;10:1806\u201313.","journal-title":"Clin J Am Soc Nephrol"},{"key":"4130_CR6","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1007\/s00401-021-02275-6","volume":"141","author":"NJ Ashton","year":"2021","unstructured":"Ashton NJ, Pascoal TA, Karikari TK, Benedet AL, Lantero-Rodriguez J, Brinkmalm G, et al. Plasma p-tau231: a new biomarker for incipient Alzheimer\u2019s disease pathology. Acta Neuropathol 2021;141:709\u201324.","journal-title":"Acta Neuropathol"},{"key":"4130_CR7","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.ebiom.2015.11.036","volume":"3","author":"M Gisslen","year":"2016","unstructured":"Gisslen M, Price RW, Andreasson U, Norgren N, Nilsson S, Hagberg L, et al. Plasma concentration of the neurofilament light protein (NFL) is a biomarker of CNS injury in HIV infection: a cross-sectional study. EBioMedicine. 2016;3:135\u201340.","journal-title":"EBioMedicine"},{"issue":"1","key":"4130_CR8","doi-asserted-by":"publisher","first-page":"14798","DOI":"10.1038\/s41598-018-33158-8","volume":"8","author":"A Abdelhak","year":"2018","unstructured":"Abdelhak A, Huss A, Kassubek J, Tumani H, Otto M.Serum GFAP as a biomarker for disease severity in multiple sclerosis. Sci Rep. 2018;8(1):14798.","journal-title":"Sci Rep"},{"key":"4130_CR9","doi-asserted-by":"publisher","first-page":"20350","DOI":"10.1038\/s41598-020-76990-7","volume":"10","author":"S Akamine","year":"2020","unstructured":"Akamine S, Marutani N, Kanayama D, Gotoh S, Maruyama R, Yanagida K, et al. Renal function is associated with blood neurofilament light chain level in older adults. Sci Rep 2020;10:20350.","journal-title":"Sci Rep"},{"key":"4130_CR10","doi-asserted-by":"publisher","first-page":"e277","DOI":"10.1212\/WNL.0000000000207419","volume":"101","author":"A Dittrich","year":"2023","unstructured":"Dittrich A, Ashton NJ, Zetterberg H, Blennow K, Zettergren A, Simren J, et al. Association of chronic kidney disease with plasma NfL and other biomarkers of neurodegeneration: the H70 birth cohort study in Gothenburg. Neurology 2023;101:e277\u2013e88.","journal-title":"Neurology"},{"issue":"5","key":"4130_CR11","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1001\/jamaneurol.2023.0199","volume":"80","author":"S Janelidze","year":"2023","unstructured":"Janelidze S, Barthelemy NR, He Y, Bateman RJ, Hansson O.Mitigating the associations of kidney dysfunction with blood biomarkers of Alzheimer disease by using phosphorylated tau to total tau ratios. JAMA Neurol. 2023;80(5):516\u201322.","journal-title":"JAMA Neurol"},{"key":"4130_CR12","doi-asserted-by":"crossref","unstructured":"Stocker H, Beyer L, Trares K, Perna L, Rujescu D, Holleczek B, et al. Association of kidney function with development of Alzheimer disease and other dementias and dementia-related blood biomarkers. JAMA Network Open. 2023;6(1).","DOI":"10.1001\/jamanetworkopen.2022.52387"},{"key":"4130_CR13","doi-asserted-by":"publisher","first-page":"7841","DOI":"10.1038\/s41598-022-11557-2","volume":"12","author":"E Rebelos","year":"2022","unstructured":"Rebelos E, Rissanen E, Bucci M, Jaaskelainen O, Honka MJ, Nummenmaa L, et al. Circulating neurofilament is linked with morbid obesity, renal function, and brain density. Sci Rep 2022;12:7841.","journal-title":"Sci Rep"},{"issue":"5","key":"4130_CR14","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1053\/j.ajkd.2021.04.016","volume":"78","author":"LA Inker","year":"2021","unstructured":"Inker LA, Titan S.Measurement and estimation of GFR for use in clinical practice: core curriculum 2021. Am J Kidney Dis. 2021;78(5):736\u201349.","journal-title":"Am J Kidney Dis"},{"issue":"13","key":"4130_CR15","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1001\/jama.2023.17002","volume":"330","author":"ME Grams","year":"2023","unstructured":"Grams ME, Coresh J, Matsushita K, Ballew SH, Sang Y, et al. Estimated glomerular filtration rate, albuminuria, and adverse outcomes: an individual-participant data meta-analysis. JAMA. 2023;330(13):1266\u201377. Writing Group for the CKDPC.","journal-title":"JAMA"},{"key":"4130_CR17","doi-asserted-by":"crossref","unstructured":"Ahn JW, Hwang J, Lee M, Kim JH, Cho HJ, Lee HW, et al. Serum neurofilament light chain levels are correlated with the infarct volume in patients with acute ischemic stroke. Medicine (Baltimore). 2022;101(39).","DOI":"10.1097\/MD.0000000000030849"},{"key":"4130_CR18","doi-asserted-by":"publisher","first-page":"36791","DOI":"10.1038\/srep36791","volume":"6","author":"P Shahim","year":"2016","unstructured":"Shahim P, Gren M, Liman V, Andreasson U, Norgren N, Tegner Y, et al. Serum neurofilament light protein predicts clinical outcome in traumatic brain injury. Sci Rep. 2016;6:36791.","journal-title":"Sci Rep"},{"key":"4130_CR19","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S0304-3940(00)01697-9","volume":"297","author":"C Hesse","year":"2001","unstructured":"Hesse C, Rosengren L, Andreasen N, Davidsson P, Vanderstichele H, Vanmechelen E, et al. Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neurosci Lett 2001;297:187\u201390.","journal-title":"Neurosci Lett"},{"key":"4130_CR20","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1038\/s41591-020-0755-1","volume":"26","author":"S Janelidze","year":"2020","unstructured":"Janelidze S, Mattsson N, Palmqvist S, Smith R, Beach TG, Serrano GE, et al. Plasma P-tau181 in Alzheimer\u2019s disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer\u2019s dementia. Nat Med 2020;26:379\u201386.","journal-title":"Nat Med"},{"issue":"2","key":"4130_CR21","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/0006-8993(71)90668-8","volume":"28","author":"LF Eng","year":"1971","unstructured":"Eng LF, Vanderhaeghen JJ, Bignami A, Gerstl B.An acidic protein isolated from fibrous astrocytes. Brain Res. 1971;28(2):351\u201354.","journal-title":"Brain Res"},{"key":"4130_CR22","doi-asserted-by":"publisher","first-page":"102810","DOI":"10.1016\/j.msard.2021.102810","volume":"50","author":"M Saraste","year":"2021","unstructured":"Saraste M, Bezukladova S, Matilainen M, Sucksdorff M, Kuhle J, Leppert D, et al. Increased serum glial fibrillary acidic protein associates with microstructural white matter damage in multiple sclerosis: GFAP and DTI. Mult Scler Relat Disord. 2021;50:102810.","journal-title":"Mult Scler Relat Disord"},{"issue":"5","key":"4130_CR23","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.1002\/ehf2.12878","volume":"7","author":"P Kashioulis","year":"2020","unstructured":"Kashioulis P, Guron CW, Svensson MK, Hammarsten O, Saeed A, Guron G.Patients with moderate chronic kidney disease without heart disease have reduced coronary flow velocity reserve. ESC Heart Fail. 2020;7(5):2797\u2013806.","journal-title":"ESC Heart Fail"},{"key":"4130_CR24","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1093\/ckj\/sfw070","volume":"9","author":"P Delanaye","year":"2016","unstructured":"Delanaye P, Ebert N, Melsom T, Gaspari F, Mariat C, Cavalier E, et al. Iohexol plasma clearance for measuring glomerular filtration rate in clinical practice and research: a review. Part 1: how to measure glomerular filtration rate with iohexol? Clin Kidney J 2016;9:682\u201399.","journal-title":"Clin Kidney J"},{"key":"4130_CR25","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","volume":"385","author":"LA Inker","year":"2021","unstructured":"Inker LA, Eneanya ND, Coresh J, Tighiouart H, Wang D, Sang Y, et al. New creatinine- and cystatin C-based equations to estimate GFR without race. N Engl J Med 2021;385:1737\u201349.","journal-title":"N Engl J Med"},{"key":"4130_CR26","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1056\/NEJMoa1114248","volume":"367","author":"LA Inker","year":"2012","unstructured":"Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med 2012;367:20\u201329.","journal-title":"N Engl J Med"},{"key":"4130_CR27","doi-asserted-by":"publisher","first-page":"e1754","DOI":"10.1212\/WNL.0000000000010111","volume":"95","author":"N Kanberg","year":"2020","unstructured":"Kanberg N, Ashton NJ, Andersson LM, Yilmaz A, Lindh M, Nilsson S, et al. Neurochemical evidence of astrocytic and neuronal injury commonly found in COVID-19. Neurology 2020;95:e1754\u2013e9.","journal-title":"Neurology"},{"issue":"5","key":"4130_CR28","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.14283\/jpad.2024.142","volume":"11","author":"HT Zheng","year":"2024","unstructured":"Zheng HT, Wu Z, Mielke MM, Murray AM, Ryan J.Plasma biomarkers of Alzheimer\u2019s disease and neurodegeneration according to sociodemographic characteristics and chronic health conditions. J Prev Alzheimers Dis. 2024;11(5):1189\u201397.","journal-title":"J Prev Alzheimers Dis"},{"key":"4130_CR29","doi-asserted-by":"crossref","unstructured":"Simren J, Andreasson U, Gobom J, Suarez Calvet M, Borroni B, Gillberg C, et al. Establishment of reference values for plasma neurofilament light based on healthy individuals aged 5\u201390 years. Brain Commun. 2022;4(4):fcac174.","DOI":"10.1093\/braincomms\/fcac174"},{"key":"4130_CR30","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1046\/j.1523-1755.2001.00016.x","volume":"60","author":"AG Norden","year":"2001","unstructured":"Norden AG, Lapsley M, Lee PJ, Pusey CD, Scheinman SJ, Tam FW, et al. Glomerular protein sieving and implications for renal failure in Fanconi syndrome. Kidney Int 2001;60:1885\u201392.","journal-title":"Kidney Int"},{"issue":"2","key":"4130_CR31","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1152\/physrev.00055.2006","volume":"88","author":"B Haraldsson","year":"2008","unstructured":"Haraldsson B, Nystrom J, Deen WM.Properties of the glomerular barrier and mechanisms of proteinuria. Physiol Rev. 2008;88(2):451\u201387.","journal-title":"Physiol Rev"},{"key":"4130_CR32","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1161\/STROKEAHA.119.024941","volume":"50","author":"FK Korley","year":"2019","unstructured":"Korley FK, Goldstick J, Mastali M, Van Eyk JE, Barsan W, Meurer WJ, et al. Serum NfL (neurofilament light chain) levels and incident stroke in adults with diabetes mellitus. Stroke 2019;50:1669\u201375.","journal-title":"Stroke"},{"key":"4130_CR33","doi-asserted-by":"crossref","unstructured":"Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJ, Mann JF, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet. 2013;382(9889).","DOI":"10.1016\/S0140-6736(13)60595-4"},{"key":"4130_CR34","doi-asserted-by":"publisher","first-page":"491","DOI":"10.7326\/M14-0743","volume":"161","author":"ED Michos","year":"2014","unstructured":"Michos ED, Wilson LM, Yeh HC, Berger Z, Suarez-Cuervo C, Stacy SR, et al. Prognostic value of cardiac troponin in patients with chronic kidney disease without suspected acute coronary syndrome: a systematic review and meta-analysis. Ann Intern Med 2014;161:491\u2013501.","journal-title":"Ann Intern Med"},{"key":"4130_CR35","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1016\/j.ekir.2020.04.031","volume":"5","author":"NR Stein","year":"2020","unstructured":"Stein NR, Zelnick LR, Anderson AH, Christenson RH, deFilippi CR, Deo R, et al. Associations between cardiac biomarkers and cardiac structure and function in CKD. Kidney Int Rep 2020;5:1052\u201360.","journal-title":"Kidney Int Rep"},{"key":"4130_CR36","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1002\/alz.12787","volume":"19","author":"A Pichet Binette","year":"2023","unstructured":"Pichet Binette A, Janelidze S, Cullen N, Dage JL, Bateman RJ, Zetterberg H, et al. Confounding factors of Alzheimer\u2019s disease plasma biomarkers and their impact on clinical performance. Alzheimers Dement 2023;19:1403\u201314.","journal-title":"Alzheimers Dement"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04130-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12882-025-04130-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-025-04130-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,9]],"date-time":"2025-05-09T18:00:14Z","timestamp":1746813614000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-025-04130-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,9]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["4130"],"URL":"https:\/\/doi.org\/10.1186\/s12882-025-04130-2","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,9]]},"assertion":[{"value":"7 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Ethics Committee of the University of Gothenburg approved the study (620-07, 2020-05523), and the research was conducted in accordance with the Helsinki Declaration. All study subjects gave informed written consent to participate.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"TA, BA and AS declare no conflict of interest. MKS and NJA declare no conflict of interest related to this manuscript. GG has given lectures and\/or served at scientific advisory boards for Boehringer Ingelheim, AstraZeneca, Bayer, Novo Nordisk, Vifor Pharma, GSK, Sanofi and Otsuka on topics not related to the content of this manuscript. HZ has served at scientific advisory boards and\/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, LabCorp, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, Novo Nordisk, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). KB has served as a consultant and at advisory boards for Abbvie, AC Immune, ALZPath, AriBio, Beckman-Coulter, BioArctic, Biogen, Eisai, Lilly, Moleac Pte. Ltd, Neurimmune, Novartis, Ono Pharma, Prothena, Quanterix, Roche Diagnostics, Sanofi and Siemens Healthineers; has served at data monitoring committees for Julius Clinical and Novartis; has given lectures, produced educational materials and participated in educational programs for AC Immune, Biogen, Celdara Medical, Eisai and Roche Diagnostics; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper. MA has received compensation for lectures and\/or advisory boards from Biogen, Gazyme and Novartis.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"231"}}